[go: up one dir, main page]

WO2013034982A3 - Immunomodulatory peptides for treatment of progressive neurodegenerative diseases - Google Patents

Immunomodulatory peptides for treatment of progressive neurodegenerative diseases Download PDF

Info

Publication number
WO2013034982A3
WO2013034982A3 PCT/IB2012/002216 IB2012002216W WO2013034982A3 WO 2013034982 A3 WO2013034982 A3 WO 2013034982A3 IB 2012002216 W IB2012002216 W IB 2012002216W WO 2013034982 A3 WO2013034982 A3 WO 2013034982A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neurodegenerative diseases
progressive neurodegenerative
immunomodulatory peptides
neurodegenerative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/002216
Other languages
French (fr)
Other versions
WO2013034982A2 (en
Inventor
Robert E. W. Hancock
Neil R. Cashman
Cheryl WELLINGTON
Carina Mallard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of WO2013034982A2 publication Critical patent/WO2013034982A2/en
Publication of WO2013034982A3 publication Critical patent/WO2013034982A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods for the prevention or treatment of neurodegenerative disease are provided. The methods provide administering an innate defense regulator (IDR) peptide composition to the subject in an amount effective to reduce or eliminate the symptoms and causes of neurodegenerative disease including neuroinflammation.
PCT/IB2012/002216 2011-09-09 2012-09-10 Immunomodulatory peptides for treatment of progressive neurodegenerative diseases Ceased WO2013034982A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533179P 2011-09-09 2011-09-09
US61/533,179 2011-09-09

Publications (2)

Publication Number Publication Date
WO2013034982A2 WO2013034982A2 (en) 2013-03-14
WO2013034982A3 true WO2013034982A3 (en) 2013-05-30

Family

ID=47832667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/002216 Ceased WO2013034982A2 (en) 2011-09-09 2012-09-10 Immunomodulatory peptides for treatment of progressive neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2013034982A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646718A (en) * 2016-02-22 2016-06-08 成都虎标行生物科技有限公司 M1 type MAP (macrophage activation peptide) and IL-2 (interleukin-2) fusion protein and fusion gene as well as expression vector and construction method of expression vector

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
SG192773A1 (en) 2011-03-18 2013-09-30 Univ Duke Peptides for suppressing inflammation
US9239332B2 (en) 2011-07-11 2016-01-19 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
US20160289287A1 (en) * 2013-08-27 2016-10-06 The University Of British Columbia Small cationic anti-biofilm and idr peptides
US10131690B2 (en) 2014-04-25 2018-11-20 Phi Pharma Sa C6S specific transporter molecules
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
EP3519425B1 (en) * 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. Polytherapy modulating cathelicidin gene expression modulation for the treatment of alzheimer's disease and other conditions
US11464824B2 (en) 2018-03-02 2022-10-11 The Food Science Institute Foundation Peptide capable of improving cognitive function
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2023278598A1 (en) * 2021-06-30 2023-01-05 Mitsubishi Tanabe Pharma Corporation Als treatment method, als pharmaceutical composition, and als diagnostic method
CN116135233A (en) * 2021-11-16 2023-05-19 中国科学院动物研究所 Application of CPE in the preparation of drugs for promoting in situ neurogenesis and treating aging-related neurodegenerative diseases
WO2025117825A1 (en) * 2023-11-27 2025-06-05 Soligenix, Inc. Compositions and methods of treatment of certain vasculitis syndromes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022444A1 (en) * 2006-08-21 2008-02-28 The University Of British Columbia Small cationic antimicrobial peptides
WO2010026489A1 (en) * 2008-09-05 2010-03-11 The University Of British Columbia Innate immunity modulators
WO2010043039A1 (en) * 2008-10-16 2010-04-22 University Of Saskatchewan Combination adjuvant formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022444A1 (en) * 2006-08-21 2008-02-28 The University Of British Columbia Small cationic antimicrobial peptides
WO2010026489A1 (en) * 2008-09-05 2010-03-11 The University Of British Columbia Innate immunity modulators
WO2010043039A1 (en) * 2008-10-16 2010-04-22 University Of Saskatchewan Combination adjuvant formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STREIT W.J. ET AL.: "Microglia and Neuroinflammation: a Pathological Perspective", J. NEUROINFLAMMATION., vol. 1, no. 14, 30 July 2004 (2004-07-30), pages 1 - 4, XP021010065, Retrieved from the Internet <URL:URL:http://www.jneuroinflammation.com/content/1/1/14> [retrieved on 20130304] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646718A (en) * 2016-02-22 2016-06-08 成都虎标行生物科技有限公司 M1 type MAP (macrophage activation peptide) and IL-2 (interleukin-2) fusion protein and fusion gene as well as expression vector and construction method of expression vector

Also Published As

Publication number Publication date
WO2013034982A2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013034982A3 (en) Immunomodulatory peptides for treatment of progressive neurodegenerative diseases
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
IN2015KN00414A (en)
HK1215934A1 (en) Peptide therapeutics and methods for using same
MX2019000586A (en) Treatment of amd using aav sflt-1.
IN2014MN00948A (en)
IN2014KN02830A (en)
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
WO2012170918A3 (en) Methods of treatment for retinal diseases
IN2014MN00986A (en)
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EA201590880A1 (en) COMPOSITIONS AND METHODS OF TREATMENT PROTEINOPATHY
IN2015DN00376A (en)
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
EP4285994A3 (en) Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
BR112014005025A2 (en) pharmaceutical composition for use in the treatment of a neurodegenerative disease
IN2014MN02056A (en)
WO2014161004A3 (en) Compositions and methods for the delivery of drugs to the ocular surface by contact lenses
GB201118201D0 (en) Novel peptides
MX376783B (en) Liposome-based immunotherapy
IN2014CN00510A (en)
WO2014039074A3 (en) Therapeutic compositions and related methods
NZ700467A (en) Treatments suitable for malassezia infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12830470

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12830470

Country of ref document: EP

Kind code of ref document: A2